InvestorsHub Logo
icon url

dukesking

07/17/23 12:11 AM

#412066 RE: antibluechip #412064

antibluechip, These are all good questions for our legal experts. I don’t have any educated answers for you. I personally feel that the infringement angle is the best way to effect change.
icon url

Number sleven

07/17/23 12:27 AM

#412067 RE: antibluechip #412064

ABC, The ab rating given to the generic version of Vascepa should insulate insurance companies from that type of liability. The ab rating implies that the drugs are identical. At least in the view of the FDA. gv doesn't have a CVD label, that is a patent issue.
Sleven,
icon url

rosemountbomber

07/17/23 4:57 AM

#412069 RE: antibluechip #412064

I believe Sleven’s answer is best. But one must not forget, there were cardiac events in the Vascepa arm of R-I.